Roche Holding AG (RHHVF)
OTHER OTC:RHHVF
RHHVF Stock Chart & Stats
$400.00
-$1.53(-0.53%)
At close: 4:00 PM EST
$400.00
-$1.53(-0.53%)
Day’s Range― - ―
52-Week Range$277.00 - $490.33
Previous CloseN/A
Volume301.00
Average Volume (3M)14.00K
Market Cap
$317.24B
Enterprise Value$276.08B
Total Cash (Recent Filing)$15.48B
Total Debt (Recent Filing)$31.64B
Price to Earnings (P/E)20.3
Beta0.38
Next Earnings
Jul 23, 2026EPS Estimate
13.64Next Dividend Ex-DateN/A
Dividend Yield2.62%
Share Statistics
EPS (TTM)10.63
Shares Outstanding702,562,700
10 Day Avg. Volume3,014
30 Day Avg. Volume13,999
Financial Highlights & Ratios
PEG Ratio0.36
Price to Book (P/B)7.73
Price to Sales (P/S)4.25
P/FCF Ratio18.55
Enterprise Value/Market Cap0.87
Enterprise Value/Revenue4.49
Enterprise Value/Gross Profit6.10
Enterprise Value/Ebitda12.19
Forecast
1Y Price Target
$442.02Price Target Upside10.50% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering13
EPS Forecast (FY)25.52
Revenue Forecast (FY)$79.56B
Bulls Say, Bears Say
Bulls Say
Adjuvant Breast Cancer Market OpportunityGiredestrant's improved tolerability and potential to permit switching from aromatase inhibitor therapy could expand the eligible adjuvant patient pool and attract patients who avoid more toxic combination regimens.
Clinical Efficacy In Relapsing Multiple SclerosisFENhance trials reported substantial reductions in relapses and brain lesions versus the comparator, indicating fenebrutinib could deliver a meaningful efficacy advantage in relapsing multiple sclerosis.
Diagnostics Technology And DiversificationNew sequencing, sensor, and automated mass spectrometry platforms position Diagnostics to capture incremental share through faster and more flexible testing, continuous glucose monitoring integration, and broad laboratory workflows, helping offset pharmaceutical patent pressures.
Bears Say
Analyst Caution From Prior Trial OutcomesLegacy high‑risk trial failures and unresolved uncertainties around endocrine sensitivity have led to analyst caution, which could sustain downside pressure if upcoming data do not reduce perceived trial risk.
Regulatory And Evidentiary HurdlesRemaining questions on statistical significance and the need for definitive randomized studies for giredestrant combinations create regulatory and payer hurdles that could delay widespread adoption.
Safety Signals In Clinical TrialsAn imbalance in fatal cases and liver toxicity signals in fenebrutinib studies raises material safety concerns that could limit regulatory clearance and clinician confidence.
Roche Holding AG News
RHHVF FAQ
What was Roche Holding AG’s price range in the past 12 months?
Roche Holding AG lowest stock price was $277.00 and its highest was $490.33 in the past 12 months.
What is Roche Holding AG’s market cap?
Roche Holding AG’s market cap is $317.24B.
When is Roche Holding AG’s upcoming earnings report date?
Roche Holding AG’s upcoming earnings report date is Jul 23, 2026 which is in 104 days.
How were Roche Holding AG’s earnings last quarter?
Roche Holding AG released its earnings results on Jan 29, 2026. The company reported $10.625 earnings per share for the quarter, missing the consensus estimate of $10.803 by -$0.178.
Is Roche Holding AG overvalued?
According to Wall Street analysts Roche Holding AG’s price is currently Undervalued.
Does Roche Holding AG pay dividends?
Roche Holding AG pays a Annually dividend of $10.972 which represents an annual dividend yield of 2.62%. See more information on Roche Holding AG dividends here
What is Roche Holding AG’s EPS estimate?
Roche Holding AG’s EPS estimate is 13.64.
How many shares outstanding does Roche Holding AG have?
Roche Holding AG has 702,562,700 shares outstanding.
What happened to Roche Holding AG’s price movement after its last earnings report?
Roche Holding AG reported an EPS of $10.625 in its last earnings report, missing expectations of $10.803. Following the earnings report the stock price went up 10.522%.
Which hedge fund is a major shareholder of Roche Holding AG?
Currently, no hedge funds are holding shares in RHHVF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Roche Holding AG
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Switzerland, Germany, the United States, Austria, Netherlands, the United Kingdom, France, Belgium, and internationally. The company offers pharmaceutical products for treating oncology, neuroscience, infectious, immunology, cardiovascular and metabolism, ophthalmology, and respiratory, as well as anemia, cancer, dermatology, hemophilia, inflammatory and autoimmune, neurological, and transplantation. It also offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases. In addition, the company supplies diagnostic instruments and reagents. It has a research collaboration agreement with Synlogic, Inc. for the discovery of a novel synthetic biotic for the treatment of inflammatory bowel disease (IBD). The company was founded in 1896 and is headquartered in Basel, Switzerland.
RHHVF Company Deck
RHHVF Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlighted strong operational execution: group sales +7% (Pharma +9%), core operating profit +13% and meaningful pipeline momentum with multiple positive Phase III readouts, approvals, a record 10 NMEs entering Phase III and launches (AXELIOS sequencing, mass spec, dengue test). Roche also secured a major U.S. government agreement and committed large U.S. investments. Material headwinds were acknowledged — notably Diagnostics headwinds from China pricing reforms (CHF 579m impact), FX and cash-flow/working capital pressures, higher taxes reducing EPS momentum, LOE effects (~CHF 700m) and safety/regulatory scrutiny (fenebrutinib liver signal). Management provided 2026 guidance (mid-single-digit sales growth, high single-digit Core EPS growth) and expects Diagnostics headwinds to diminish in 2026 and largely disappear by 2027. Overall, the positives from sales, margin expansion, prolific pipeline and strategic investments substantially outweighed the operational and market challenges discussed.View all RHHVF earnings summariesRHHVF Stock 12 Month Forecast
Average Price Target
$442.02
▲(10.50% Upside)
Technical Analysis
Ownership Overview
―
Insiders
10.97% Mutual Funds
0.03% Other Institutional Investors
75.93% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---